RABL6A inhibits tumor-suppressive PP2A/AKT signaling to drive pancreatic neuroendocrine tumor growth

Hyperactivated AKT/mTOR signaling is a hallmark of pancreatic neuroendocrine tumors (PNETs). Drugs targeting this pathway are used clinically, but tumor resistance invariably develops. A better understanding of factors regulating AKT/mTOR signaling and PNET pathogenesis is needed to improve current...

詳細記述

保存先:
書誌詳細
出版年:J Clin Invest
主要な著者: Umesalma, Shaikamjad, Kaemmer, Courtney A., Kohlmeyer, Jordan L., Letney, Blake, Schab, Angela M., Reilly, Jacqueline A., Sheehy, Ryan M., Hagen, Jussara, Tiwari, Nitija, Zhan, Fenghuang, Leidinger, Mariah R., O’Dorisio, Thomas M., Dillon, Joseph, Merrill, Ronald A., Meyerholz, David K., Perl, Abbey L., Brown, Bart J., Braun, Terry A., Scott, Aaron T., Ginader, Timothy, Taghiyev, Agshin F., Zamba, Gideon K., Howe, James R., Strack, Stefan, Bellizzi, Andrew M., Narla, Goutham, Darbro, Benjamin W., Quelle, Frederick W., Quelle, Dawn E.
フォーマット: Artigo
言語:Inglês
出版事項: American Society for Clinical Investigation 2019
主題:
Research Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC6436899/
https://ncbi.nlm.nih.gov/pubmed/30721156
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI123049
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料